Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Benzocaine study

This article was originally published in The Tan Sheet

Executive Summary

The Consumer Healthcare Products Association should implement a series of controls in its upcoming study to rate the efficacy of 10% and 20% benzocaine in relieving toothache pain, FDA states in a Feb. 28 letter. The agency responds to CHPA's call for revised protocol on the group's three-arm, placebo-controlled, toothache dose-response trial submitted in December (1"The Tan Sheet" Jan. 17, 2005, p. 11). FDA's recommendations include use of a visual analog scale score, in addition to the Dental Pain Scale, for pain assessment. The agency also suggests that "assessment of onset, duration and magnitude of pain relief be compared to the outcome of a global satisfaction assessment" in order to demonstrate clinically significant differences in treatments. CHPA should include "instructions for uniform selection and dosing of rescue medications" in the protocol for both pediatric and adult subjects. The study is being conducted in response to FDA's 2004 request for a larger clinical trial to study benzocaine for toothaches (2"The Tan Sheet" July 5, 2004, p. 9)...

You may also be interested in...



Benzocaine Study Revisions Proposed; Trial Slated To Begin In Spring

The Consumer Healthcare Products Association Oral Discomfort Task Group will commence a study on benzocaine 10% and 20% in early March

Benzocaine Monograph For Toothache Requires Further Study – FDA

FDA says benzocaine-containing oral analgesic manufacturers will have to conduct a larger clinical trial to support a Category I (safe and effective) classification for the treatment of toothaches

QUOTED. 3 April 2020. Minetta Liu.

Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.

Topics

UsernamePublicRestriction

Register

PS099144

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel